Eligible women with breast cancer in Thailand now have access to a new therapy, NERLYNX® (neratinib), for the first time. The launch of NERLYNX provides an important new treatment option for women diagnosed with human epidermal growth factor receptor 2 positive (HER2+) breast cancer. This follows the approval of NERLYNX by the Thai FDA in December 2024 as a single agent for the treatment of early-stage HER2+ breast cancer, and in combination with capecitabine for the treatment of advanced or metastatic HER2+ breast cancer.
